Glutamine

Glutamine (abbreviated Gln or Q; IUPAC name (2*S*)-2,5-diamino-5-oxopentanoic acid; molecular formula C₅H₁₀N₂O₃; molecular mass 146.14 Da) is a polar, uncharged proteinogenic α-amino acid encoded by the genetic code codons CAA and CAG. First isolated in 1883 by Ernst Schulze and E. Bosshard from sugar beet (Beta vulgaris) juice and structurally confirmed via enzymatic hydrolysis from gliadin in 1932 by Chibnall and Westall, glutamine is the γ-carboxylic acid amide derivative of glutamate and the one-methylene-longer homolog of asparagine. Its side chain terminates in a resonance-stabilized, planar carboxamide group (–CH₂–CH₂–CONH₂) that remains unionized across the entire physiological pH spectrum (α-COOH pK_a1 = 2.17, α-NH₃⁺ pK_a2 = 9.13, isoelectric point pI = 5.65).

Because every glutamine molecule carries two nitrogen atoms—an α-amino nitrogen and a γ-amide nitrogen—in a neutral, non-toxic zwitterionic structure, L-glutamine is the most abundant free amino acid in human blood plasma (maintained at 0.50 to 0.80 mM, representing ~20% of the total circulating free amino-acid pool) and in intracellular skeletal muscle pools (~15–20 mM). Nutritionally classified as conditionally essential during catabolic trauma, sepsis, burns, or rapid cell proliferation, glutamine performs four central physiological roles: (1) non-toxic systemic transport of ammonia from peripheral tissues and astrocytes to the liver and kidneys; (2) obligate donation of its γ-amide nitrogen via glutamine amidotransferases for de novo purine, pyrimidine, NAD⁺, and amino-sugar biosynthesis; (3) anaplerotic replenishment of mitochondrial α-ketoglutarate (glutaminolysis) in lymphocytes, enterocytes, and cancer cells; and (4) formation of polar hydrogen-bonding networks in protein structures, whose pathological expansion in CAG trinucleotide repeat disorders drives polyglutamine (polyQ) neurodegenerative aggregation.

ATP-Dependent Ammonia Fixation by Glutamine Synthetase (GS / GLUL)

Free ammonia (NH₃ / NH₄⁺, pK_a = 9.25) is neurotoxic at plasma concentrations above 50–100 μM, disrupting astrocyte osmotic balance and depleting mitochondrial α-ketoglutarate. Peripheral tissues (skeletal muscle, lungs, and brain astrocytes) detoxify ammonia by fixing it onto glutamate via the ATP-dependent enzyme glutamine synthetase (GS, encoded by GLUL; EC 6.3.1.2) in a two-step catalytic sequence:

1. γ-Glutamyl Phosphate Activation: ATP transfers its terminal γ-phosphate group to the γ-carboxylate oxygen of L-glutamate (coordinated by two divalent Mg²⁺ or Mn²⁺ ions), generating a high-energy enzyme-bound acyl-phosphate intermediate, γ-glutamyl phosphate, plus ADP.
2. Nucleophilic Attack by Ammonia: Unprotonated NH₃ attacks the carbonyl carbon of γ-glutamyl phosphate to displace inorganic phosphate (P_i) and release L-glutamine:

L-Glutamate + NH₄⁺ + ATP → L-Glutamine + ADP + P_i + H⁺ (ΔG°′ = −14.2 kJ/mol)

As elucidated by Earl Stadtman and colleagues in Escherichia coli, bacterial glutamine synthetase is a dodecameric (12-subunit) double-ring assembly regulated by two classic mechanisms: (a) cumulative feedback inhibition by eight downstream end-products of glutamine metabolism (including tryptophan, histidine, alanine, glycine, AMP, CTP, glucosamine-6-phosphate, and carbamoyl phosphate), and (b) reversible covalent adenylylation (attachment of AMP from ATP onto a conserved tyrosine Tyr397 residue) catalyzed by the bifunctional adenylyltransferase/uridylyltransferase cascade (GlnE / PII signaling protein) in response to the intracellular [glutamine] / [α-ketoglutarate] ratio. In the mammalian liver, glutamine synthetase is restricted to a thin 1-to-3-hepatocyte-wide ring of perivenous ("scavenger") hepatocytes surrounding the central hepatic vein, capturing residual NH₄⁺ that escapes the periportal urea cycle before venous blood enters systemic circulation.

Mitochondrial Glutaminases (GLS1/GLS2) and Renal Acid-Base Ammoniagenesis

When circulating glutamine reaches target organs (periportal hepatocytes, renal proximal tubules, intestinal enterocytes, or presynaptic neurons), mitochondrial phosphate-activated glutaminase hydrolyzes its γ-amide bond to regenerate glutamate and ammonium:

L-Glutamine + H₂O → L-Glutamate + NH₄⁺

Mammals express two glutaminase genes with distinct physiological roles:

• GLS2 (Liver-type Glutaminase, LGA): Expressed in periportal hepatocytes (where released NH₄⁺ enters mitochondrial carbamoyl phosphate synthetase I to initiate the urea cycle) and transcriptionally induced by the tumor suppressor p53.
• GLS1 (Kidney-type Glutaminase, KGA and splice isoform GAC): Expressed in the kidney, brain, and proliferating cells. During metabolic acidosis, the renal proximal convoluted tubule up-regulates GLS1 and mitochondrial glutamate dehydrogenase (GDH) (stabilizing their mRNAs via pH-sensitive AU-rich elements) to extract both nitrogens from glutamine as two NH₄⁺ ions (excreted into the urine to titrate H⁺) while converting the remaining α-ketoglutarate carbon skeleton via gluconeogenesis into two new bicarbonate (HCO₃⁻) ions that return to blood plasma to restore systemic pH.

Obligate Amide Nitrogen Donation in Purine, Pyrimidine, and Amino-Sugar Synthesis

Whereas free ammonia is too toxic to accumulate at the millimolar concentrations required by biosynthetic enzymes, glutamine amidotransferases (GATases) contain a dedicated glutaminase module that hydrolyzes L-glutamine on demand and channels nascent NH₃ through a solvent-shielded intramolecular protein tunnel directly to an acceptor synthetase site. Two evolutionary superfamilies of GATases supply nitrogen for cellular anabolism:

1. De Novo Purine Ring Synthesis: Glutamine phosphoribosylpyrophosphate (PRPP) amidotransferase (GPAT) (a Class-II N-terminal nucleophile, Ntn-hydrolase, whose N-terminal Cys1 attacks the γ-amide of glutamine) and FGAR amidotransferase (PurL) donate the N9 and N3 ring nitrogens of the purine bicycle, while GMP synthetase uses glutamine to aminate xanthosine monophosphate (XMP) at C2 to form guanosine monophosphate (GMP).
2. De Novo Pyrimidine Ring Synthesis: Cytosolic carbamoyl phosphate synthetase II (CPS-II, part of the trifunctional CAD enzyme complex) uses a Class-I Cys–Histidine–Glutamate triad to hydrolyze glutamine and donate the N3 ring nitrogen of all pyrimidines, while CTP synthetase (CTPS) transfers a glutamine γ-amide nitrogen onto C4 of UTP to generate cytidine triphosphate (CTP).
3. NAD⁺, Amino Sugars, Asparagine, and Tryptophan: NAD⁺ synthetase uses glutamine to convert nicotinic acid adenine dinucleotide (NaAD) into NAD⁺; glutamine:fructose-6-phosphate amidotransferase (GFAT1/2) transfers the glutamine amide group to fructose-6-phosphate to form glucosamine-6-phosphate (the rate-limiting precursor of UDP-GlcNAc for O-GlcNAcylation, glycosaminoglycans, and N-glycans); and microbial anthranilate synthase and PABA synthase use glutamine to synthesize tryptophan and folate.

Anaplerotic Glutaminolysis in Proliferating Cells and Cancer

In rapidly dividing cells—such as activated T-lymphocytes, intestinal crypt stem cells, and MYC-driven tumor cells—citric acid cycle (TCA) citrate is continually exported from the mitochondria into the cytosol (and cleaved by ATP-citrate lyase into acetyl-CoA) to fuel de novo phospholipid and cholesterol membrane synthesis. To prevent the TCA cycle from collapsing due to carbon depletion, proliferating cells consume glutamine at rates 5-fold to 10-fold higher than any other amino acid via glutaminolysis:

1. Glutamine enters the cell through the neutral amino-acid transporter ASCT2 (SLC1A5) (creating the high intracellular glutamine gradient that also drives LAT1/SLC7A5 antiport import of essential leucine, which activates mTORC1).
2. Mitochondrial GLS1 hydrolyzes glutamine to glutamate, which glutamate dehydrogenase (GDH) or mitochondrial transaminases (GOT2, GPT2, PSAT1) convert into the 5-carbon TCA intermediate α-ketoglutarate (α-KG).
3. α-Ketoglutarate either proceeds oxidatively around the TCA cycle to generate NADH, FADH₂, and oxaloacetate (which transaminates to aspartate for nucleotide synthesis) or, under hypoxia or mitochondrial impairment, undergoes reductive carboxylation by NADPH-dependent isocitrate dehydrogenase (IDH1/IDH2) to synthesize isocitrate and citrate backward from α-ketoglutarate.

Polyglutamine (PolyQ) Trinucleotide Repeat Neurodegenerative Diseases

Because glutamine is encoded by the trinucleotide codon CAG, replication slippage and defective mismatch repair during meiosis or somatic maintenance can expand tandem CAG repeats within protein-coding exons. At Least nine inherited human neurodegenerative diseases—including Huntington's disease (HTT gene on chromosome 4p16.3), spinocerebellar ataxias (SCA1, SCA2, SCA3/Machado-Joseph, SCA6, SCA7, SCA17), spinal and bulbar muscular atrophy (SBMA / Kennedy's disease), and dentatorubral-pallidoluysian atrophy (DRPLA)—are caused by coding CAG expansions that produce elongated polyglutamine (polyQ) tracts.

In the normal huntingtin protein, the N-terminal polyQ tract contains 6 to 35 consecutive glutamines and remains soluble as a flexible amphipathic α-helix / random-coil ensemble. When the tract expands to ≥ 36–40 glutamines (with complete penetrance at ≥ 40 repeats), the side-chain carboxamides (–CONH₂) and main-chain peptide groups of adjacent glutamine chains interlock into Max Perutz's "polar zipper"—a hyperstable, cross-β amyloid sheet held together by doubly hydrogen-bonded glutamine ladders. Furthermore, the lag time before fibril nucleation decreases and the clinical age of onset shortens inversely with repeat length according to an exponential decay relationship relative to polyQ tract length above the ~37-repeat thermodynamic threshold, sequestering transcription factors (such as CBP and TBP) and impairing ubiquitin-proteasome and autophagic clearance in striatal medium spiny neurons.

Why is glutamine—rather than glutamate or alanine—the most abundant free amino acid in human blood?

Glutamine possesses three ideal chemical properties for systemic nitrogen transport: (1) unlike free ammonia (NH₄⁺), it is uncharged and non-toxic at millimolar concentrations; (2) unlike glutamate, it is electrically neutral at pH 7.4 (rapidly crossing cell membranes via SLC1A5/SLC38 transporters) and does not activate excitatory NMDA or AMPA glutamate receptors; and (3) unlike alanine (which carries 1 nitrogen atom per 3 carbons), glutamine carries 2 nitrogen atoms per 5 carbons—both an α-amino group and a readily hydrolyzable γ-amide group usable directly by amidotransferases.

How does glutamine influx activate the mTORC1 growth signaling pathway?

Intracellular glutamine does not directly bind the mTORC1 leucine sensor Sestrin2; instead, cells first concentrate glutamine inside the cytosol via the Na⁺-coupled symporter ASCT2 (SLC1A5). This steep outward-directed glutamine gradient then powers the obligatory heterodimeric antiporter LAT1–4F2hc (SLC7A5/SLC3A2), which exports one intracellular glutamine molecule in strict 1:1 exchange for importing one extracellular essential branched-chain or aromatic amino acid (specifically L-leucine, phenylalanine, or tryptophan). Imported leucine binds Sestrin2 and releases GATOR2 to activate Rag GTPases and mTORC1 at the lysosomal surface (Nicklin et al., 2009).

Why do polyglutamine diseases exhibit genetic anticipation across generations?

Long tracts of tandem CAG repeats (> 28–35 repeats) form stable intramolecular hairpin loops on the nascent lagging or template DNA strand during spermatogenesis and base-excision repair (mediated by MutSβ / MSH2–MSH3). When DNA polymerase synthesizes across the slipped hairpin, extra CAG triplets are incorporated into the germline allele. Because longer polyQ tracts nucleate β-sheet polar zippers faster, children who inherit an expanded allele (particularly through paternal transmission in Huntington's disease) develop symptoms at a substantially younger age and with greater severity than their affected parent (genetic anticipation).

1. Woolfolk, C. A., Shapiro, B., & Stadtman, E. R. (1966). "Regulation of glutamine synthetase: I. Purification and properties of glutamine synthetase from Escherichia coli." Archives of Biochemistry and Biophysics, 116, 177–192. https://doi.org/10.1016/0003-9861(66)90026-990026-9)
2. Perutz, M. F., Johnson, T., Suzuki, M., & Finch, J. T. (1994). "Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases." Proceedings of the National Academy of Sciences, 91(12), 5355–5358. https://doi.org/10.1073/pnas.91.12.5355
3. Nicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H., Nyfeler, B., Yang, H., Hild, M., Kung, C., Wilson, C., et al. (2009). "Bidirectional transport of amino acids regulates mTOR and autophagy." Cell, 136(3), 521–534. https://doi.org/10.1016/j.cell.2008.11.044
4. Altman, B. J., Stine, Z. E., & Dang, C. V. (2016). "From Krebs to clinic: Glutamine metabolism to cancer therapy." Nature Reviews Cancer, 16(10), 619–634. https://doi.org/10.1038/nrc.2016.71